EMA Authorised: Emselex (darifenacin hydrobromide) — pharmaand GmbH

View source ↗

Summary

The EMA authorised Emselex (darifenacin hydrobromide) for urinary incontinence due to urge and overactive bladder, with pharmaand GmbH as the marketing authoris…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder
• Urinary Incontinence

Drugs mentioned

• Emselex (darifenacin hydrobromide)

Snippet

Status: Authorised. Therapeutic area: Urinary Incontinence, Urge;Urinary Bladder, Overactive. MAH: pharmaand GmbH. Decision date: 14/08/2025